Evidence map›Paper›PMID 11556835›Full record

ArticleBritish journal of cancer2001

Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method.

S Casadei, L Cortesi, V Pensotti, P Radice, M Pierotti, D Amadori, D Calistri

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

S CasadeiIstituto Oncologico Romagnolo, 47100 Forlì, Italy.
L Cortesi
V Pensotti
P Radice
M Pierotti
D Amadori
D Calistri
Fondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITIstituto Oncologico Romagnolo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method set up for a sensitive and preliminary rapid screening of BRCA1 mutations. We analysed exons 11 and 16, which are known to cover slightly more than 70% of the whole coding region of the gene, subdivided into 4 amplicons and labelled with different fluorescent dUTPs. MD-CFLP was first utilised on a panel of 30 DNA samples in which the presence of single-base substitutions or small deletions/insertions had been previously identified by direct sequencing as gold standard, in order to define the optimal conditions in terms of PCR amplification and temperature of digestion. In a second step, we blindly analysed 21 DNA samples by MD-CFLP to verify its reliability. The sensitivity and specificity of MD-CFLP were both 100% in the first study, and 80% and 94%, respectively, in the blind sample assay. Our results demonstrate the capability of the MD-CFLP method to detect DNA sequence alterations in fragments of more than 1 kb. We conclude that CFLP is a powerful tool in mutational analysis, offering reliable results in a shorter time and at a lower cost than conventional methods, and its potential can be enhanced when internal fluorescent labelling and laser detection are used.

Indexed as

Germ-Line MutationBRCA1 ProteinBreast NeoplasmsDNA Mutational AnalysisDNA, NeoplasmDNA PrimersExonsFemaleFluorescent DyesGenetic Predisposition to DiseaseHumansNucleic Acid ConformationOvarian NeoplasmsPolymerase Chain ReactionPolymorphism, GeneticReproducibility of ResultsBRCA1 ProteinDNA, NeoplasmDNA PrimersFluorescent Dyes

Identifiers

PMID11556835
PMCPMC2375072
OpenAlexW2075351225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.